HEDS Home Page

Welcome to the Health Economics and Decision Science Section of ScHARR

The Section

The purpose of HEDS is to promote excellence in health care resource allocation decisions. HEDS makes major contributions in areas that include the valuation of health, the analysis of health policy, welfare and equity, technology appraisal,evidence synthesis, econometrics and information sciences.

We also lead several national research collaborations, supervise PhD students, contribute to Masters programmes, deliver external training courses and provide input to national committees. Find out more about our activities in the most recent issue of our newsletter.

Latest publications

Atienzo, E. E., Kaltenthaler, E. and Baxter, S. K.  Interventions to prevent youth violence in Latin America: a systematic review. International Journal of Public Health. October 2016.

Basarir, H., Brennan, A., Jacques, R.M., Pollard, D., et al. Cost-effectiveness of structured education in children with type-1 diabetes mellitus. International Journal of Technology Assessment in Health Care. October 2016

Kearns, B., Pandor, A., Stevenson, M., Hamilton, J., et al. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. October 2016

Consultancy, Innovation & Knowledge Transfer

HEDS delivers a vibrant portfolio of consultancy-funded research to the pharmaceutical and medical devices sector and the NHS. It utilises our broad range of skills and is complemented by tailored training courses covering a full range of research methods, as well as policy issues such as pricing and reimbursement. If you want to discuss any opportunities, please contact the ScHARR IKT team.

Latest project news

Best Practices for the Design, Implementation, Analysis, and Reporting of Oncology Trials with High Rates of Treatment Switching
Nick Latimer has been part of a team working with the Center for Medical Technology Policy’s Green Park Collaborative to develop best practice recommendations on managing treatment switching in oncology drug trials. The guidance document document has just been published. October 2016

Real World Data: guidance from the DSU
The NICE Decision Support Unit, based in HEDS, has published a report that provides guidance on the use of real world data (RWD) for the estimation of treatment effects in NICE decision making.
October 2016

Section Director

Professor Simon Dixon

Deputy Section Director

Dr Eva Kaltenthaler

HEDS blog

The best way to keep up with our work and our impact on policy is to read the HEDS Blog. With over 70,000 hits from over 110 different countries recent blog posts also feature on Twitter: